Results 231 to 240 of about 21,171,014 (388)

Massive Intra‐Abdominal Pseudotumor in a Patient With Hemophilia A Treated With Emicizumab: A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Hemophilic pseudotumors, a rare complication of bleeding disorders, are more common in settings with limited access to clotting factor concentrates. Subcutaneous emicizumab, a relatively novel therapy for hemophilia A, was investigated for its ability to stabilize an inoperable pseudotumor in a patient with factor VIII deficiency in an under ...
C. J. Kilach, C. Njuguna, F. Njuguna, C. M. Wanjiku, K. F. Molitor, I. A. Janson, S. M. Mbunya, A. D. Shapiro, J. Sagar, A. Greist   +9 more
wiley   +1 more source

Paediatric Subanalysis of TSUBASA, Assessing Physical Activity, Bleeding, Quality of Life and Safety in People with Haemophilia A Receiving Emicizumab. [PDF]

TH Open
Nogami K, Amano K, Sawada A, Nagao A, Nagae C, Nojima M, Suzuki N, Kawano M, Shimura T, Sugao Y, Fujii T.   +10 more
europepmc   +1 more source

Treatment Adherence, Satisfaction and Quality of Life of Adult Patients with Severe Haemophilia a: Results from a Real-World Survey of Physicians and Patients [PDF]

V. Merla, Sheena Thakkar, Jasmine Healy, Ella Morton, Kieran Wynne-Cattanach, Nathan Ball, Sophie Lai, Chris Blazos, Hanna Salehi   +8 more
openalex   +1 more source

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A

, 2021
Maria Elisa Mancuso, Tina Biss, Kathelijn Fischer, Monika Maas Enriquez, MacGregor Steele, Maria Wang, D. Tseneklidou‐Stoeter, Sanjay Ahuja, Gili Kenet   +8 more
openalex   +1 more source

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

Haemophilia, 2018
P. Collins, R. Liesner, Michael Makris, K. Talks, P. Chowdary, Elizabeth Chalmers, Georgina W. Hall, Anne Riddell, C. Percy, C. R. M. Hay, Daniel P. Hart   +10 more
semanticscholar   +1 more source

Interfacility Collaboration for Hemophilia Care in Japan: A Retrospective Database Study Using a Japanese Healthcare Claims Database

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims In Japan, about 6000 patients with hemophilia A (PwHA) are separately cared for at ~1000 clinics or hospitals. Interfacility collaboration (IFC) between hemophilia treatment centers and “satellite” medical facilities located closer to patients is necessary to eliminate care disparities.
Ei Kinai, Masako Yamaguchi, Akira Shirahata   +2 more
wiley   +1 more source

Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half-Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study. [PDF]

Haemophilia
Solimeno LP, Gualtierotti R, Guido E, Acquati Lozej J, Cristini E, Ciavarella A, Arcudi S, Carulli C, Pieri L, Siboni SM, Peyvandi F.   +10 more
europepmc   +1 more source

Rebalancing Hemostasis: Fitusiran as a First‐in‐Class RNAi Therapy in Hemophilia A and B

Health Science Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background and Aims Fitusiran is a first‐in‐class RNA interference (RNAi) therapy that lowers antithrombin (AT) to rebalance hemostasis in people with Hemophilia A or B, with or without inhibitors. Its recent FDA approval marks a major shift toward factor‐independent prophylaxis.
Raza Ur Rehman, Rida Fatima, Aymar Akilimali   +2 more
wiley   +1 more source

Clinical, humanistic, and economic burden of haemophilia A in China: findings from a real-world survey. [PDF]

Orphanet J Rare Dis
Feng J, Dou L, Chen J, Fang Y, Cheng Y, Li S.   +5 more
europepmc   +1 more source

Evaluation of coagulation disorders and iron deficiency in women with heavy menstrual bleeding

International Journal of Gynecology &Obstetrics, Volume 172, Issue 1, Page 250-254, January 2026.
Abstract Objective To explore the incidence of congenital bleeding disorders (CBD), which may result in anemia, in a large cohort of women referred for heavy menstrual bleeding (HMB) in a specialized gynecologic unit. Methods Between January 2022 and January 2024, all women referred for HMB were screened.
Lucia Rugeri, Yelena Fruchou, Caroline Brodbeck, Marianne Bastien, Amandine Lioux, Giulia Gouy, Marion Cortet, Gil Dubernard, Yesim Dargaud   +8 more
wiley   +1 more source